- Home
- ASRT vs CUE Comparison
ASRT vs CUE Comparison
Compare ASRT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- CUE
- Stock Information
- Founded
- ASRT 1995
- CUE 2014
- Country
- ASRT United States
- CUE United States
- Employees
- ASRT N/A
- CUE N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- CUE Health Care
- Exchange
- ASRT Nasdaq
- CUE Nasdaq
- Market Cap
- ASRT 57.9M
- CUE 58.9M
- IPO Year
- ASRT 1997
- CUE 2018
- Fundamental
- Price
- ASRT $0.66
- CUE $0.64
- Analyst Decision
- ASRT Strong Buy
- CUE Strong Buy
- Analyst Count
- ASRT 3
- CUE 3
- Target Price
- ASRT $3.08
- CUE $3.00
- AVG Volume (30 Days)
- ASRT 284.6K
- CUE 163.7K
- Earning Date
- ASRT 05-12-2025
- CUE 05-12-2025
- Dividend Yield
- ASRT N/A
- CUE N/A
- EPS Growth
- ASRT N/A
- CUE N/A
- EPS
- ASRT N/A
- CUE N/A
- Revenue
- ASRT $119,001,000.00
- CUE $7,991,000.00
- Revenue This Year
- ASRT N/A
- CUE N/A
- Revenue Next Year
- ASRT $11.71
- CUE $25.99
- P/E Ratio
- ASRT N/A
- CUE N/A
- Revenue Growth
- ASRT N/A
- CUE 13.83
- 52 Week Low
- ASRT $0.51
- CUE $0.45
- 52 Week High
- ASRT $1.80
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ASRT 50.57
- CUE 38.40
- Support Level
- ASRT $0.67
- CUE $0.61
- Resistance Level
- ASRT $0.71
- CUE $0.71
- Average True Range (ATR)
- ASRT 0.04
- CUE 0.06
- MACD
- ASRT 0.00
- CUE -0.00
- Stochastic Oscillator
- ASRT 52.69
- CUE 20.67
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.